Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ladarixin ophthalmic solution single and multiple ascending dose study in healthy volunteers
NL-OMON58834Phase 1Completed
- Sponsor
- Dompé
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ladarixin in ocular inflammation, sponsored by Dompé. Primary endpoint: Primary endpoint(s). Started Feb 2026; status: completed.
02
Drugs
ladarixin
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NL-OMON58834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58834.